LYNN K GORDON, M.D., PH.D.
Medical Practice at Stein Plz, Los Angeles, CA
License number
California G57153
Category
Medical Practice
Type
Ophthalmology
Address
Address
100 Stein Plz, Los Angeles, CA 90095
Phone
(310) 825-5000
Personal information
See more information about LYNN K GORDON at radaris.comName
Address
Phone
4786 Queen Victoria Rd, Woodland Hills, CA 91364
55 Church St UNIT 1302, Los Gatos, CA 95030
5273 Countryside Dr, San Diego, CA 92115
396 S Miraleste Dr, San Pedro, CA 90732
3295 Wall Ave, Sn Bernrdno, CA 92404
Organization information
See more information about LYNN K GORDON at bizstanding.comThe Braun/Gordon Living Trust, Dated 12/26/90, Jonathan Braun and Lynn K Gordon, Co-Trustees
3924 Hilton Head Way, Los Angeles, CA 91356
Status:
Inactive
Member:
Gordon Braun Enterprises, L.p (Member)
Professional information
District Operations Manager At U.s. Bank
Position:
District Operations Manager at U.S. Bank, V.P. Item Processing/Reconcilement Services Manager at PFF Bank & Trust
Location:
Greater Los Angeles Area
Industry:
Banking
Work:
U.S. Bank
since Mar 2009
-
District Operations Manager
PFF Bank & Trust
since Mar 2006
-
V.P. Item Processing/Reconcilement Services Manager
PFF Bank & Trust
May 2002 - Mar 2006
-
V.P.,Reconcilement Services and Vendor Liason Manager
PFF Bank & Trust
Feb 1997 - May 2002
-
Reconcilement Services Manager
Education:
Mt. San Antonio College
Dr. Lynn K Gordon, Los Angeles CA - MD (Doctor of Medicine)
Specialties:
Ophthalmology
Address:
Jules Stein Eye Institute UCLA
100 Stein Plz, Los Angeles 90095
(310) 825-3090 (Phone)
100 Stein Plz, Los Angeles 90095
(310) 825-3090 (Phone)
Certifications:
Ophthalmology, 1990
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
Jules Stein Eye Institute UCLA
100 Stein Plz, Los Angeles 90095
Ronald Reagan UCLA Medical Center
757 Westwood Plz, Los Angeles 90095
100 Stein Plz, Los Angeles 90095
Ronald Reagan UCLA Medical Center
757 Westwood Plz, Los Angeles 90095
Education:
Medical School
Harvard Medical School
Graduated: 1984
Mt Auburn Hosp
University Of California-Los Angeles
Harvard Medical School
Graduated: 1984
Mt Auburn Hosp
University Of California-Los Angeles
Nucleic Acids For The Diagnosis And Treatment Of Giant Cell Arteritis
US Patent:
6743903, Jun 1, 2004
Filed:
Jan 18, 2000
Appl. No.:
09/484577
Inventors:
Lynn K. Gordon - Tarzana CA
Lee Goodglick - Los Angeles CA
Melissa Goldman - Los Angeles CA
Lee Goodglick - Los Angeles CA
Melissa Goldman - Los Angeles CA
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
C07H 2104
US Classification:
536 231, 435 691, 435455, 435471, 4352523, 4353201, 435810, 435 6
Abstract:
This invention provides nucleic acids and methods for making and using them. The compositions and methods of the invention are used to diagnose and treat Giant Cell Arteritis (GCA).
Emp2 Antibodies And Their Therapeutic Uses
US Patent:
2014007, Mar 13, 2014
Filed:
Oct 28, 2013
Appl. No.:
14/064956
Inventors:
Lynn K. Gordon - Tarzana CA, US
Kaori Dadgostar - Los Angeles CA, US
Madhuri Wadehra - Manhattan Beach CA, US
Kathleen A. Kelly - Pacific Palisades CA, US
Anna M. Wu - Sherman Oaks CA, US
Kaori Dadgostar - Los Angeles CA, US
Madhuri Wadehra - Manhattan Beach CA, US
Kathleen A. Kelly - Pacific Palisades CA, US
Anna M. Wu - Sherman Oaks CA, US
Assignee:
The Regents of The University of California - Oakland CA
International Classification:
C07K 16/30
US Classification:
4241391, 435 723, 5303873, 5303879, 5303913, 5303917
Abstract:
The present invention provides methods and compositions useful in the treatment or prevention of infections and cancer. The methods and compositions inhibit the entry of into a host cell expressing EMP2 by interfering with the interaction between the and EMP2. The methods and compositions target cancers which express or overexpress EMP2 nucleic acids and polypeptides by targeting EMP2.
Emp2 Antibodies And Their Therapeutic Uses
US Patent:
2013023, Sep 5, 2013
Filed:
Nov 26, 2012
Appl. No.:
13/684901
Inventors:
Lynn K. Gordon - Tarzana CA, US
Kaori Shimazaki - Los Angeles CA, US
Madhuri Wadehra - Manhattan Beach CA, US
Kathy A. Kelly - Pacific Palisades CA, US
Anna M. Wu - Sherman Oaks CA, US
Kaori Shimazaki - Los Angeles CA, US
Madhuri Wadehra - Manhattan Beach CA, US
Kathy A. Kelly - Pacific Palisades CA, US
Anna M. Wu - Sherman Oaks CA, US
Assignee:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA - Oakland CA
International Classification:
C07K 16/30, A61K 45/06, A61K 39/395
US Classification:
4241391, 5303879, 5303873, 435 723, 5303913, 5303917
Abstract:
The present invention provides methods and compositions useful in the treatment or prevention of infections and cancer. The methods and compositions inhibit the entry of into a host cell expressing EMP2 by interfering with the interaction between the and EMP2. The methods and compositions target cancers which express or overexpress EMP2 nucleic acids and polypeptides by targeting EMP2.
Emp2 Antibodies And Their Therapeutic Uses
US Patent:
8318906, Nov 27, 2012
Filed:
Oct 8, 2008
Appl. No.:
12/682032
Inventors:
Jonathan Braun - Tarzana CA, US
Lynn K. Gordon - Tarzana CA, US
Kaori Shimizaki - Los Angeles CA, US
Kathy A. Kelly - Sherman Oaks CA, US
Anna M. Wu - Sherman Oaks CA, US
Lynn K. Gordon - Tarzana CA, US
Kaori Shimizaki - Los Angeles CA, US
Kathy A. Kelly - Sherman Oaks CA, US
Anna M. Wu - Sherman Oaks CA, US
Assignee:
The Regents of The University of California - Oakland CA
International Classification:
C07K 16/00, C12P 21/08, A61K 39/395, G01N 33/566
US Classification:
5303871, 4241581, 436501, 5303873, 5303881, 5303892
Abstract:
The present invention provides methods and compositions useful in the treatment or prevention of infections and cancer. The methods and compositions inhibit the entry of into a host cell expressing EMP2 by interfering with the interaction between the and EMP2. The methods and compositions target cancers which express or overexpress EMP2 nucleic acids and polypeptides by targeting EMP2.
Epithelial Membrane Protein-2 (Emp2) And Proliferative Vitroretinopathy (Pvr)
US Patent:
2013000, Jan 3, 2013
Filed:
Nov 18, 2010
Appl. No.:
13/510877
Inventors:
Lynn K. Gordon - Tarzana CA, US
Shawn A. Morales - Pasadena CA, US
David Telander - Carmichael CA, US
Jonathan Braun - Tazana CA, US
Shawn A. Morales - Pasadena CA, US
David Telander - Carmichael CA, US
Jonathan Braun - Tazana CA, US
Assignee:
The United States Government Department of Veteran's Affair - Washington DC
The Regents of the University of California - Oakland CA
The Regents of the University of California - Oakland CA
International Classification:
A61K 39/395, C12N 5/079, A61P 27/02
US Classification:
4241351, 4241721, 4241391, 4241331, 4241781, 435375
Abstract:
Methods of preventing retinal detachment associated with proliferative vitreoretinopathy are provided by administering agents which antagonize the activity or function of EMP2 to subjects at risk of the detachment.
Epithelial Membrane Protein 2 (Emp2) Binding Reagents And Their Therapeutic Uses In Ocular Diseases
US Patent:
2013003, Feb 7, 2013
Filed:
Feb 22, 2011
Appl. No.:
13/580100
Inventors:
Lynn K. Gordon - Tarzana CA, US
Jonathan Braun - Tarzana CA, US
Shawn A. Morales - Pasadena CA, US
David Telander - Carmichael CA, US
Madhuri Wadehra - Manhattan Beach CA, US
Jonathan Braun - Tarzana CA, US
Shawn A. Morales - Pasadena CA, US
David Telander - Carmichael CA, US
Madhuri Wadehra - Manhattan Beach CA, US
Assignee:
United States Government Department of Veterans Affairs - Washington DC
The Regents of the University of California - Oakland CA
The Regents of the University of California - Oakland CA
International Classification:
A61K 39/395, A61P 27/02, A61K 31/7088
US Classification:
4241351, 4241721, 514 44 A
Abstract:
A method is disclosed for treating diseases or disorders of the eye involving undesired expression of vascular endothelial growth factor (VEGF) by administration of endothelial membrane protein 2 (EMP2) inhibitor. The present invention relates to the direct treatment of macular degeneration, particularly age-related macular degeneration (AMD), by administering an EMP2 inhibitor intraocularly or systemically.
Prevention Of Chlamydia Infection Using Sirna
US Patent:
8648052, Feb 11, 2014
Filed:
Oct 8, 2007
Appl. No.:
11/868788
Inventors:
Jonathan Braun - Tarzana CA, US
Lynn K. Gordon - Tarzana CA, US
Kaori Shimazaki - Los Angeles CA, US
Kathy A. Kelly - Pacific Palisades CA, US
Lynn K. Gordon - Tarzana CA, US
Kaori Shimazaki - Los Angeles CA, US
Kathy A. Kelly - Pacific Palisades CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
C12N 15/11, A61K 39/118
US Classification:
514 44A, 4242631
Abstract:
The present invention provides methods and compositions useful in the treatment or prevention of infections. The methods and compositions inhibit the entry of into a host cell expressing EMP2 by interfering with the interaction between the and EMP2. The compositions include EMP2 nucleic acids and polypeptides as well as anti-EMP2 antibodies.
Emp2 Antibodies And Their Therapeutic Uses
US Patent:
2013034, Dec 26, 2013
Filed:
Aug 21, 2013
Appl. No.:
13/972670
Inventors:
Lynn K. Gordon - Tarzana CA, US
Kaori Shimazaki Dadgostar - Los Angeles CA, US
Madhuri Wadehra - Manhattan Beach CA, US
Kathleen A. Kelly - Pacific Palisades CA, US
Anna M. Wu - Sherman Oaks CA, US
Kaori Shimazaki Dadgostar - Los Angeles CA, US
Madhuri Wadehra - Manhattan Beach CA, US
Kathleen A. Kelly - Pacific Palisades CA, US
Anna M. Wu - Sherman Oaks CA, US
Assignee:
The Regents of The University of California - Oakland CA
International Classification:
C07K 16/30
US Classification:
4241391, 5303879, 5303873, 5303917, 5303913, 435 71
Abstract:
The present invention provides methods and compositions useful in the treatment or prevention of infections and cancer. The methods and compositions inhibit the entry of into a host cell expressing EMP2 by interfering with the interaction between the and EMP2. The methods and compositions target cancers which express or overexpress EMP2 nucleic acids and polypeptides by targeting EMP2.